KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Shares Issued (2018 - 2025)

Esperion Therapeutics' Shares Issued history spans 8 years, with the latest figure at $72.6 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 19.91% year-over-year to $72.6 million; the TTM value through Dec 2025 reached $72.6 million, down 19.94%, while the annual FY2025 figure was $72.6 million, 19.94% down from the prior year.
  • Shares Issued reached $72.6 million in Q4 2025 per ESPR's latest filing, down from $90.6 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $90.6 million in Q4 2024 to a low of -$14.8 million in Q3 2024.
  • Average Shares Issued over 5 years is $24.3 million, with a median of $9.0 million recorded in 2024.
  • Peak YoY movement for Shares Issued: plummeted 171.38% in 2021, then surged 1415.17% in 2022.
  • A 5-year view of Shares Issued shows it stood at $6.5 million in 2021, then surged by 238.17% to $22.0 million in 2022, then surged by 138.44% to $52.4 million in 2023, then surged by 72.89% to $90.6 million in 2024, then decreased by 19.91% to $72.6 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Shares Issued are $72.6 million (Q4 2025), $90.6 million (Q4 2024), and -$14.8 million (Q3 2024).